We are live on ! Find out more
INDP icon

Indaptus Therapeutics

25 hedge funds and large institutions have $2.71M invested in Indaptus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

131% more call options, than puts

Call options by funds: $30K | Put options by funds: $13K

24% less funds holding

Funds holding: 3325 (-8)

34% less capital invested

Capital invested by funds: $4.08M → $2.71M (-$1.38M)

63% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 8

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

Holders
25
Holders Change
-8
Holders Change %
-24.24%
% of All Funds
0.49%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
3
Reduced
8
Closed
10
Calls
$30K
Puts
$13K
Net Calls
+$17K
Net Calls Change
-$11K

INDP Hedge Fund Activity: Q4 2019 in Review

25 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2019, worth a combined $2.71M — down 34% from $4.08M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of INDP and 2 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 3 added.

The largest buyer was ETF Managers Group, adding an estimated $149K. The largest seller was Taylor Frigon Capital Management, exiting entirely with an estimated $302K sold.

  • 25 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2019, down from 33 in Q3 2019.
  • Funds reported $2.71M of Indaptus Therapeutics stock for Q4 2019, down 34% quarter-over-quarter.
  • 2 funds opened new Indaptus Therapeutics positions in Q4 2019 and 10 closed out, a net change of -8 holders.
  • The largest Indaptus Therapeutics buyer in Q4 2019 was ETF Managers Group, an estimated $149K added.
  • The largest Indaptus Therapeutics seller in Q4 2019 was Taylor Frigon Capital Management, an estimated $302K sold.

Based on aggregated 13F filings for Q4 2019.